Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Takakusagi, Yoichi ^a   Matsumoto, Shingo ^a   Saito, Keita ^a   Matsuo, Masayuki ^a   Kishimoto, Shun ^a   Wojtkowiak, Jonathan W ^b   DeGraff, William ^a   Kesarwala, Aparna H ^a   Choudhuri, Rajani ^a   Devasahayam, Nallathamby ^a   Subramanian, Sankaran ^a   Munasinghe, Jeeva P ^c   Gillies, Robert J ^b   Mitchell, James B ^a   Hart, Charles P ^d   Krishna, Murali C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d Threshold Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVOFOSFAMIDE; PYRUVIC ACID; ANTINEOPLASTIC AGENT; NITROIMIDAZOLE DERIVATIVE; OXYGEN; PHOSPHORAMIDE MUSTARD; PRODRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL VIABILITY; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ELECTRON SPIN RESONANCE; FEMALE; HT 29 CELL LINE; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MITOCHONDRIAL OXYGEN CONSUMPTION; MITOCHONDRIAL RESPIRATION; MOLECULAR IMAGING; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN CONSUMPTION; QUANTITATIVE ANALYSIS; SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL CARCINOMA CELL LINE; TISSUE OXYGENATION; TUMOR HYPOXIA; TUMOR XENOGRAFT; ANIMAL; CELL HYPOXIA; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; METABOLISM; MITOCHONDRION; TIME; TUMOR CELL LINE;

MURINAE; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MITOCHONDRIA; NITROIMIDAZOLES; OXYGEN; OXYGEN CONSUMPTION; PHOSPHORAMIDE MUSTARDS; PRODRUGS; PYRUVIC ACID; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907450550     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107995     Document Type: Article

References (35)

1. Hockel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. Journal of the National Cancer Institute 93: 266-276.
2. Cardenas-Navia LI, Yu D, Braun R.D., Brizel DM, Secomb TW, et al. (2004) Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing. Cancer research 64: 6010-6017.
3. Chaplin DJ, Olive PL, Durand RE (1987) Intermittent blood flow in a murine tumor: radiobiological effects. Cancer research 47: 597-601.
4. Kimura H, Braun RD, Ong E.T., Hsu R., Secomb TW, et al. (1996) Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer research 56: 5522-5528.
5. Sorg BS, Moeller BJ, Donovan O, Cao Y., Dewhirst MW (2005) Hyperspectral imaging of hemoglobin saturation in tumor microvasculature and tumor hypoxia development. Journal of biomedical optics 10: 44004.
6. Gray LH, Conger AD, Ebert M, Hornsey S., Scott OC (1953) The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. The British journal of radiology 26: 638-648.
7. Bush RS, Jenkin RD, Allt W.E., Beale FA, Bean H, et al. (1978) Definitive evidence for hypoxic cells influencing cure in cancer therapy. The British journal of cancer Supplement 3: 302-306.
8. Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nature reviews Cancer 6: 583-592.
9. Brown JM (2007) Tumor hypoxia in cancer therapy. Methods in enzymology 435: 297-321.
10. Brizel DM, Sibley GS, Prosnitz L.R., Scher RL, Dewhirst MW (1997) Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. International journal of radiation oncology, biology, physics 38: 285-289.
11. Fukumura D, Jain RK (2007) Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvascular research 74: 72-84.
12. Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer metastasis reviews 26: 225-239.
13. Wilson WR, Hay MP (2011) Targeting hypoxia in cancer therapy. Nature reviews Cancer 11: 393-410.
14. Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nature reviews Cancer 4: 437-447.
15. Teicher BA, Sartorelli AC (1980) Nitrobenzyl halides and carbamates as prototype bioreductive alkylating agents. Journal of medicinal chemistry 23: 955-960.
16. Duan JX, Jiao H, Kaizerman J., Stanton T, Evans JW, et al. (2008) Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem 51: 2412-2420.
17. Ganjoo KN, Cranmer LD, Butrynski J.E., Rushing D., Adkins D, et al. (2011) A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma. Oncology 80: 50-56.
18. Weiss GJ, Infante JR, Chiorean E.G., Borad MJ, Bendell JC, et al. (2011) Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clinical cancer research 17: 2997-3004.
19. Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, et al. (2010) Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood 116: 1524-1527.
20. Sun JD, Liu Q, Wang J., Ahluwalia D, Ferraro D, et al. (2012) Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clinical cancer research 18: 758-770.
21. Meng F, Evans JW, Bhupathi D, Banica M., Lan L, et al. (2012) Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Molecular cancer therapeutics 11: 740-751.
22. Matsumoto S, Hyodo F, Subramanian S., Devasahayam N, Munasinghe J, et al. (2008) Low-field paramagnetic resonance imaging of tumor oxygenation and glycolytic activity in mice. The Journal of clinical investigation 118: 1965-1973.
23. Matsumoto S, Batra S, Saito K., Yasui H, Choudhuri R, et al. (2011) Antiangiogenic agent sunitinib transiently increases tumor oxygenation and suppresses cycling hypoxia. Cancer research 71: 6350-6359.
24. Saito K, Matsumoto S, Yasui H., Devasahayam N, Subramanian S, et al. (2012) Longitudinal imaging studies of tumor microenvironment in mice treated with the mTOR inhibitor rapamycin. PloS one 7: e49456.
25. Saito K, Matsumoto S, Devasahayam N., Subramanian S, Munasinghe JP, et al. (2012) Transient decrease in tumor oxygenation after intravenous administration of pyruvate. Magnetic resonance in medicine 67: 801-807.
26. (1996) National Research council. Guide for the care and use of laboratory animals. Washington DC: National Academy Press.
27. Suit HD, Maimonis P, Michaels H.B., Sedlacek R (1981) Comparison of hyperbaric oxygen and misonidazole in fractionated irradiation of murine tumors. Radiat Res 87: 360-367.
28. Suit HD, Suchato C (1967) Hyperbaric oxygen and radiotherapy of a fibrosarcoma and of a squamous-cell carcinoma of C3H mice. Radiology 89: 713-719.
29. Fu KK, Rayner PA, Lam KN (1984) Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion. Int J Radiat Oncol Biol Phys 10: 1473-1478.
30. Yasui H, Matsumoto S, Devasahayam N., Munasinghe JP, Choudhuri R, et al. (2010) Low-field magnetic resonance imaging to visualize chronic and cycling hypoxia in tumor-bearing mice. Cancer research 70: 6427-6436.
31. Farrar CT, Kamoun WS, Ley C.D., Kim YR, Catana C, et al. (2011) Sensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma model. PloS one 6: e17228.
32. Guichard M, Lespinasse F, Malaise EP (1986) Influence of buthionine sulfoximine and misonidazole on glutathione level and radiosensitivity of human tumor xenografts. Radiation research 105: 115-125.
33. Nelson SJ, Kurhanewicz J, Vigneron D.B., Larson PE, Harzstark AL, et al. (2013) Metabolic imaging of patients with prostate cancer using hyperpolarized [1-(1)(3)C]pyruvate. Sci Transl Med 5: 198ra108.
34. Zhang X, Prasanta D, Martinez G., Rajeshkumar NV, Le A, et al. (2012) Imaging biomarkers: a comparison of hyperpolarized 13C MRS and diffusion-weighted MRI. ISMRM 20th Annual Meeting 0271.
35. Cairns RA, Bennewith KL, Graves E.E., Giaccia AJ, Chang DT, et al. (2009) Pharmacologically increased tumor hypoxia can be measured by 18F-Fluoroazomycin arabinoside positron emission tomography and enhances tumor response to hypoxic cytotoxin PR-104. Clin Cancer Res 15: 7170-7174.